GS9.F stock -30.15% pre-market on XETRA: H100 Group €0.117 flags liquidity risk

GS9.F stock opened the pre-market session on XETRA sharply lower, sliding -30.15% to €0.117 after heavy selling. We see elevated volume at 12,981 shares, more than double the average of 5,498, which signals short-term pressure. The move follows weak fundamentals: negative EPS of -0.02 and a negative P/E. In this pre-market top losers briefing we unpack price action, valuation metrics, liquidity risks and what our model suggests next for H100 Group AB N on XETRA in Germany.

Price action and market context for GS9.F stock

The immediate fact: GS9.F stock is trading at €0.117, down 30.15% on the session with a day high of €0.1235 and a day low of €0.117. Market cap is €39,224,278 and the stock shows high short-term volatility—one-day change sits at -30.15% while the 1M change is -40.31%. The share count is 335,250,237, which constrains liquidity despite a recent jump in trading volume.

Valuation and financial metrics driving the selloff

H100 Group AB N posts negative earnings and stretched valuation ratios: EPS is -0.02 and reported P/E is -5.85, pointing to losses. Price averages are weak: 50-day average €0.1774 and 200-day average €0.37421, underlining a persistent downtrend. Price-to-book is low at 0.22, but price-to-sales is extreme at 136.82, reflecting very low trailing revenue per share versus current market price.

Liquidity, volume and trading signals for GS9.F stock

Volume is 12,981 versus an average of 5,498, giving a relative volume of 2.36, which indicates outsized interest in the selloff. On technicals, RSI is 48.86 and ADX 18.94 suggesting no strong trend, but OBV and MFI point to distribution. Low absolute price and wide bid-ask spreads on XETRA increase execution risk for larger orders.

Sector and peer context: healthcare comparisons

H100 Group AB N is listed in Healthcare, Medical – Healthcare Information Services. The healthcare sector average metrics show healthier margins and larger liquidity than GS9.F. Sector peers typically trade at far higher price-to-sales and have more stable earnings, so H100 Group’s negative margins and high EV-to-sales ratios present a contrast that likely pressured sentiment.

Meyka AI rates GS9.F with a score out of 100

Meyka AI rates GS9.F with a score out of 100: 62.39/100 (Grade B, Suggestion: HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. We note the company-level rating from independent models shows weaker fundamentals, but our composite grade balances short-term risk with longer-term asset value.

Meyka AI forecast and price target for GS9.F stock

Meyka AI’s forecast model projects a fair value around €0.218 compared with the current €0.117, implying an upside of 86.82% if model assumptions hold. Forecasts consider book value per share (€5.69), cash per share (€0.83) and current operating metrics. Forecasts are model-based projections and not guarantees. For further live data see Meyka GS9.F page and sector updates from Reuters healthcare news or market structure at Deutsche Börse XETRA.

Final Thoughts

GS9.F stock is the pre-market top loser on XETRA after a -30.15% drop to €0.117 driven by weak fundamentals, thin liquidity and an active sell volume of 12,981 shares. Valuation signals are mixed: a low price-to-book (0.22) sits against extreme price-to-sales (136.82) and a negative P/E (-5.85). Our Meyka AI grade of 62.39/100 (B, HOLD) reflects these trade-offs and weighs sector comparisons and liquidity risk. Meyka AI’s forecast model projects €0.218, implying +86.82% from the current price, but this is a model projection and not a guarantee. Traders should watch execution risk, the 50- and 200-day averages (€0.1774, €0.37421) as resistance, and any corporate updates. We continue to monitor XETRA order flow and sector news; large holders or fresh funding disclosures would materially change the outlook. For active portfolios, treat GS9.F as high-volatility, speculative exposure rather than a core holding.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.